Tutogen Medical — Regeneration Technologies — Merger or Acquisition (November 2007)
27 slides from Tutogen Medical's merger presentation, Nov 16, 2007
Slide 1: Filed by Tutogen Medical, Inc. Pursuant to Rule 425
Filed by Tutogen Medical, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Regeneration Technologies, Inc. Commission File No.: 0-31271 Forward Looking Statements This communication contains
Slide 2: Powering Forward - Stephens Fall Investment Conference
POWERING Technologies, Regeneration® Stephens Brian Chairman, K. Hutchison Fall President FORWARD Investment Inc. and CEO Conference
Slide 3: Forward Looking Statements
FORWARD Technologies, Regeneration® risks significantly The Private information and uncertainties, Securities LOOKING greater Inc. contained regulation Litigation such STATEMENT herein as by our Reform is the ability not FDA. aAct prospectus toActual maintain of 1995 results and provides ourdoes exi
Slide 4: More Information
MORE Technologies, Regeneration® Tutogen The registration Shareholders with statement/prospectus, these incorporated Inc., Regeneration Technologies Information meeting may preceding proposed be PO the documents, INFORMATION obtained of SEC, Medical, Box paragraph. stockholders, statement, about by
Slide 5: Merger Announcement
MERGER Technologies, Regeneration® On reaching November a ANNOUNCEMENT broad Inc. 13,range 2007,ofRegeneration markets and Technologies, medical specialties Inc. and withTutogen a diversified Medical, mixInc. of implants announced through a merger established to createdistribution the leadingchannel
Slide 6: About the Transaction
ABOUT Technologies, Regeneration® Terms Pro •*Ownership Tax-free, Tutogen Expect ~ 5655% 45% forma million ofTTG RTI to THE the shareholders ownership stock-for-stock close shares of shareholders deal: shareholders Inc. TRANSACTION theincompany outstanding Q1 ofwill 2008, theexchange receive combine
Slide 7: Combined Leadership
COMBINED Technologies, Regeneration® Executive •Board – Tom Total Brian Guy Bob focused Seven Five Johnston, Mayer, Rose, of members of Hutchison, directors Directors: 12 on Leadership: VP, directors international LEADERSHIP President Inc. VP of CFO from Chairman Tutogen Finance and RTIactivities Se
Slide 8: Combined Company Implant Segments
IMPLANT Technologies, Regeneration® Dent. Int’l BGS Surgical Other Dental Spine Sports Combined Tutogen RTI 6% 28% 14% 10% 48% 26% 14% 6% 43% 10% 32% Med 17% Spec Company SEGMENTS 25% 16% 5% Inc.
Slide 9: Combined Company Implant Segments
COMBINED Technologies, Regeneration® Sports Spine Combined Tutogen RTI Bone General Breast Ophthalmology Hernia Urology Dental Other International ENT Graft Reconstruction Medicine Orthopedic Substitutes IMPLANT Inc. SEGMENTS
Slide 10: Key Distributors
KEY14% Technologies, Regeneration® ZMH Int’l Other MSD Combined Tutogen RTI 6% 28% DISTRIBUTORS 60% 37% 58% 22% 34% Company 14% 27% Inc.
Slide 11: Who We Are
WHO Technologies, Regeneration® Began Leading Our Two-tier Allograft Xenograft Extensive Access BioCleanse portfolio WE operations toprovider technology –largest tissue –ARE donor ® bovine of Inc. sterilization products recovery xenograft of in tissue based biologic 1998 platform serves program –tis
Slide 12: Who We Are - Orthopedic Markets
WHO Technologies, Regeneration® We Oral/ Reconstructive/ Sports Spine Trauma RTI $1.5 $25 are Billion Billion Maxillofacial WE Medicine Biologics positioned ARE Orthopedic Orthobiologics Inc. Revision for in all Orthopedic Device major Surgery Market orthopedic Industry Tissue Repair; markets
Slide 13: Revenue by Business Categories
REVENUE (in Technologies, Regeneration® Nine % SPORTS SPINE BONE GENERAL $30,719 $26,950 80.2% 14.0% 63,176 48,112 31.3% TOTAL 25.2% $54,879 $68,706 Inc/Dec thousands) Months 29.5% -58.6% 4,326 GRAFT 1,793 CORE REVENUES 18,651 10,348 MEDICINE ORTHOPEDICS CATEGORIES 2,441 3,737 Ended 2.5% Inc. 53.1%
Slide 14: Who We Are - Biologics Landscape
WHO Technologies, Regeneration® Biologics RTI Stem Platelet Hyaluranic Bone Sports Cartilage/Ligament (excluding Machined/Tooled isCell, Graft WE present Med Concentration, Product ARE Autograft) 1% Injections, Substitutes: Inc. in 75% Spine: Landscape Repair: of 22% 2% 56% the 17%2% biologics – Ind
Slide 15: BioCleanse Differentiates Our Platform
WHO Technologies, Regeneration® BioCleanse® Proprietary, The Maintain Scientifically BIOCLEANSE®: Over Third New Half Party WEClinical England Million ARE Validated, patented, Undisputed, differentiates Inc.Utility Journal Sterilized FDA FDAofSafe, of reviewed our Implant Reviewed; Allografts Medici
Slide 16: Where We're Going
WHERE Technologies, Regeneration® Positive NON human Tutogen CryoLife Optimizing Spine Xeno BGS distribution distribution EXCLUSIVE distribution donated changes agreement WE’RE agreement distribution Inc. tissue to –GOING ––Zimmer –business Wright Orthofix/Blackstone Stryker agreement –Nov. for Dec.
Slide 17: Recent Activities: Spine
RECENT Technologies, Regeneration® Distribution Agreement Attractively Stryker We Our maintain are customers serving Agreement recently ACTIVITIES: ispositions and our aInc. are the base posting supply order rapidly most –for June RTI filling agreement asignificant competitive SPINE potentially incr
Slide 18: Where We're Going: Sports Medicine
WHERE SPORTS TECHNOLOGIES, Regeneration® Sports $ Q3:05 BTS +56% $5.00 +69% 2007 $6.00 2006 2005 +80.5% +90% $7.00 $8.00 $0.00 $1.00 $2.00 $3.00 $4.00 ?Qtr We Direct Excellent in 4321millions tissue have 1st Medicine; sales WE’RE MED qtr full recall; position of force control highe Positive GOING: l
Slide 19: Where We're Going: Sports Medicine Allograft Market
WHERE TECHNOLOGIES, Regeneration® Sports Segment Allograft: Bone ?Soft Market Surgeons BTB Tissue Tendon Medicine; tendons (in WE’RE is$126 use implants constrained $Bone millions) alternative provide $139 We GOING: (BTB) INC. $61 are $153 optimal by 2006 addressing $67 tendons $65 shortage $168 SPO
Slide 20: Where We're Going: Sports Medicine BTB Products
WHERE TECHNOLOGIES, Regeneration® RTI Higher Native Adjustable BTB Assembled Select® BTB revenue WE’RE BTB —BTB and —launch limited GOING: INC. margin linelaunch technology can May SPORTS perdouble unit 2006 July maximizes MED 2007 the availability donor yields of BTB over time
Slide 21: Where We're Going: Bone Graft Substitutes
WHERE TECHNOLOGIES, Regeneration® Bone $ Product Market $205 In $221 Introduce Surgeons $143 $127 Synthetics (RTI) DBM BMP Growth Largest $893 $731 RTI Weinstore have millions confined meeting Graft 2006 2007E distributor for Factors the WE’RE continue new 2007 Substitutes; right to price/use 1-2-st
Slide 22: Recent Activities: Zimmer Agreement
RECENT TECHNOLOGIES, Regeneration® Exclusive New Flowable Offers Initial Agreement Zimmer RTI Provides bone allograft shipments surgeons Agreement isRTI and paste ACTIVITIES: 10-year among is with amoldable bone provides base better are many distribution significant paste; –INC. with expected May pe
Slide 23: Where We're Going: Xenograft
WHERE TECHNOLOGIES, Regeneration® Xenograft; $2.3 Biologics Limited Metals Allograft, $ Xenograft Autograft, in millions billion &supply WE’RE Synthetics, are $855 will supply $797 Facilitates market preferred contribute of GOING: allows donor for INC. $648 steady biologics intissue further signific
Slide 24: Where We're Going: Xenograft Interference Screw
WHERE TECHNOLOGIES, Regeneration® Be Image The Research the femoral slices leader WE’RE indicates interference of inaXenograft; CT GOING: the INC. scan Sterling® screw ofXENOGRAFT BioCleanse® oneispatient’s Interference visible in adds knee theScrew clinical at right-hand seven combines benefit mont
Slide 25: Where We're Going: Xenograft Wright Medical Agreement
WHERE TECHNOLOGIES, Regeneration® Xenograft; Agreement New A Wright multi-purpose implants has WE’RE Wright allocated to develop marketed wedge GOING: Medical INC. significant advanced version by XENOGRAFT Wright validates of resources xenograft product under xenothe to opportunity shipped implants
Slide 26: Investment Summary
INVESTMENT TECHNOLOGIES, Regeneration® Positive New Tissue Our RTI We Introduce Continued Increases are expect has developments business repair/regeneration industry inbest changes; in the new increases continued cash record most model products driven SUMMARY flow Excellent in dynamic for INC. in gi
Slide 27: Powering Forward
POWERING FORWARD TECHNOLOGIES, Regeneration® INC.
Regeneration Technologies — Merger or Acquisition (November 2007) on 6ix